ROARABLE
FREE $100K
Today Screener Big Ideas Track Record 💰 $100K Arena 🎲 Predictions 🏛️ Insiders 8 Analysts
Stock Ratings / Health Care / EIKN / options
SCTX (43) SABS (38) AGEN (29) IPSC (18) ⌘ Pro Terminal →

Eikon Therapeutics Inc. (EIKN) Options Positioning, Max Pain & Unusual Sweeps

$5.68 +6.97% NASDAQ • Live Quote vs Prior Daily Close (Synced Snapshot) EXT / AFTER-HRS: $5.74

Eikon Therapeutics Inc. (EIKN) carries a Roarable Rating of D- (Sell) with 43/100 RQD Confidence due to weak cash-flow efficiency and sensitivity to current interest rates. Wait for business cash flow and institutional buying to improve before committing fresh capital.

ROARABLE D- • SELL / AVOID Cap $287.6M
📤 Share Live RQD Speedometer Card: 𝕏 Post Reddit StockTwits ⬇ Live SVG Card
⚡ INSTANT AI QUANT PREVIEW • $0 FREE TIER Click Any Pre-Computed AI Quant Specialist Briefing on EIKN Below — or Connect Your Own ChatGPT / Claude
🤖 Mara Quenwick • AI Quant Lead (Click for Instant Brief) Is EIKN stock a Buy, Hold, or Sell right now according to Roarable's RQD model?
▼

As of 2026-11-03, Eikon Therapeutics Inc. (NASDAQ: EIKN) is rated D- (Sell / SELL) by Roarable's 5-pillar RQD engine with a composite confidence score of 43/100 at a spot price of $5.68 (+6.97% 1D, market cap $287.6M). Pillar breakdown: Fundamental Cash Engine 10/20, Institutional 13F & Options Flow 3/20, Executive Insider Alignment 13/20, FRED Macro Regime Fit 8/20, and SEC Balance-Sheet Forensics 9/20. Active quantitative signal LIQUIDITY_TAILWIND (BEARISH, conviction undefined/100) notes: undefined.

✓ Pre-computed one-to-many AI Quant brief
🤖 Ellis Vennor • AI Peer & Flow Quant (Click for Instant Brief) How does EIKN compare to SCTX and SABS in the Health Care sector?
▼

Within the Health Care sector (Biotechnology: Biological Products (No Diagnostic Substances)), EIKN carries a Roarable D- (43/100 RQD), trailing P/E of N/A, gross margin of —, and ROIC of —. By comparison, SCTX (Scribe Therapeutics Inc.) holds a D- grade (43/100 RQD, P/E N/A, ROIC —, cap $291.9M) and SABS (SAB Biotherapeutics Inc.) posts a D- grade (38/100 RQD, P/E 22.1x, ROIC -27.4%, cap $304.8M). Among the 5-stock peer group, SABS leads on earnings multiple (22.1x) while IPSC leads on capital efficiency (-14.1% ROIC).

✓ Pre-computed one-to-many AI Quant brief
🤖 Gideon Ashmere • AI SEC 10-K Forensics (Click for Instant Brief) What are the biggest fundamental strengths and SEC risk factors for EIKN?
▼

Per EIKN's SEC EDGAR XBRL 10-K filing (FY2025, filed 2025-12-31, CIK 0001861123), Eikon Therapeutics Inc. generated $249.8M in revenue, $0 in net income, and $0 in free cash flow against $594.7M in total assets and $0 in total debt. Key quantitative strengths: Established market leader in Health Care with deep daily trading liquidity.. Primary risk factors monitored: Company executives have done more routine share selling than personal cash buying lately.. Institutional options positioning shows a 50% call / 50% put premium split.

✓ Pre-computed one-to-many AI Quant brief
🤖 AI Quant Disclosure: Roarable Analysts are proprietary AI Quant Specialists — not human financial advisors. Pre-computed one-to-many briefings above are free; interactive 1-on-1 Q&A, custom AI sifting/indicator alerts, and personal ChatGPT/Claude MCP connections require a $9.95/mo Pro account (currently waitlist-only).
INTERACTIVE SCENARIO DECK:
🛡️ Portfolio Crash X-Ray
EXT / AFTER-HRS: $5.74 (+1.06%)🧬 Disciplined Float (-0.40% YoY Shares)⚙️ Cash Engine: 10/20 (D) • 3.2% FCF Margin
Verify 90D Bucket Audit →
📊 Historical Track Record Warning: Scores below 50 (43/100 · D-) historically underperformed SPY in 71% of rolling 90-day windows (-6.7% avg 90D alpha vs SPY • 29.0% hit rate).
Audit Bucket Track Record →
RQD QUANT TACHOMETERSELL / AVOID • D-
025507510043
2-of-3 JEV AI Jury Bearish Warning
Cash
SEC
Whale

Impersonal quantitative research (0–100 RQD rubric) — not individualized investment advice. Past performance does not guarantee future results. Full Disclaimer

5-PILLAR SNOWFLAKE RADARRw D- · Rk D+
Cash (10)Whales (3)SEC (13)Macro (8)CEO (9)
Each axis scored 0–20
12M PRICE TARGET CONE-6.7% Base Target
$18 Bull$5 Base$4 Bear
📬 FREE EIKN RATING-CHANGE & BRIEFING ALERTSManage / Unsubscribe
WHALE OPTIONS SNAPSHOT: — (No Active Options Snapshot on file for EIKN)Realized 20D OHLCV Swing Band: ±12.5%
Deterministic 5-Pillar Attribution (43/100 Composite)
🔍 WHY EIKN SCORES 43/100 (D-) — TOP 3 DRIVERS2 Bullish Pillars + #1 Risk Drag
▲ #1 Bullish Driver: SEC 10-K Forensic Risk+13/20 pts (30% of score)

Altman Z-Score 3.80 (FORTRESS SAFE (>3.0)) • Piotroski F-Score 7/9

▲ #2 Bullish Driver: Cash Engine Quality+10/20 pts (23% of score)

SEC XBRL FY 2025 (10-K): 3.2% FCF Margin ($8.1M FCF) & 52% Gross Margin

▼ #1 Drag / Risk Factor: Whale & Options Positioning4/20 pts (-16 pt drag)

Put hedging (50% put share) caps near-term gamma upside (-16 pts vs max)

📈 PAST 4 QUARTERS RQD vs SUBSEQUENT RETURNQ1 → Q2 → Q3 → Current
Q1 (-3Q)
51
Grade C-$6.72+21.7% Next Q
Q2 (-2Q)
48
Grade D$8.18-32.2% Next Q
Q3 (-1Q)
46
Grade D$5.55+2.3% Next Q
Current
43
Grade D-$5.68-6.7% Hist 90D α
Trajectory: C- (51) → D- (43)Full Audit →
⚔️ ADVERSARIAL OPPOSING CASE & FORENSIC KILL-SWITCH (WHY THE BULL/BEAR THESIS COULD FAIL)CONTRARIAN TURNAROUND & SHORT-SQUEEZE DOSSIER

⚔️ Adversarial Opposing Case: What Could Spark a EIKN Turnaround Squeeze

Gideon Ashmere Forensic Desk →

While EIKN currently carries a cautious 43/100 (D-) rating due to Whale & Options Positioning (4/20), shorts face asymmetric squeeze risk if free cash flow inflects or management executes accretive buybacks.

🚀 Contrarian Squeeze Trigger #1

Established market leader in Health Care with deep daily trading liquidity.

🚀 Contrarian Squeeze Trigger #2

Options & Short-Covering Gamma: Reclaiming the 50-day SMA ($8.35) and Max Pain ($5.96) forces dealer call-delta covering toward $18.27.

🚀 Contrarian Squeeze Trigger #3

Forensic Repair Trigger: Halting share dilution (Disciplined Float (-0.40% YoY Shares)) or retiring high-cost debt immediately upgrades the SEC 10-K Forensic pillar.

🎲 LIVE PREDICTION MARKET ODDS TIED TO $EIKN• $2.4M Crowd Pool • Kalshi / Polymarket Composite
Contract: “EIKN Beats Next Quarter EPS Consensus (Dec 30, 2026) & Holds Above 200D SMA”
YES 43%NO 57%Trade / Inspect Odds →
CALL VS. PUT WHALE SHARE
— (No Active Options Snapshot)
Put/Call Ratio: — (No Active Options Snapshot)
MAX-PAIN EXPIRATION MAGNET
— (No Active Options Snapshot)
No active options chain max-pain snapshot on file
HISTORICAL 20D VOLATILITY SWING
±12.5%
Derived from 20D OHLCV bars (No Active Options Snapshot)

Active Strike Call vs. Put Concentration Ladder (EIKN)

— (No Active Options Snapshot) — No unusual CBOE strike concentration anomalies recorded in the current database snapshot for EIKN.

Sponsored / Partner SpotlightACTIVE TRADER & PROP EVALUATION DESK

Practice in Our Weekly $100,000 Paper Arena Before Risking Personal Capital

Keep your personal nest egg in cash while trading NQ, ES, Crude, and Gold momentum using institutional prop-desk buying power.

FTC Disclosure: Roarable may receive partner referral compensation at no cost to you. Partner relationships never influence RQD scores.

🏆 Enter Free $100K Paper Arena →
ON-DEMAND RQD QUANT WORKSHOP • SPONSORED / PARTNER SPOTLIGHTHosted by Perry Belcher & Roarable Forensic Quant Desk

Red-Light Warning Desk: Spotting SEC Cash-Flow & Dilution Risks Before Downgrades (Featuring EIKN)

  • ✓Walkthrough of EIKN's RQD Radar, SEC cash-conversion gap & downside invalidation levels
  • ✓3 asymmetric Bear/Hedge frameworks when 10-year Treasury yields stay elevated
  • ✓Includes nightly RQD rating-change & forensic signal email alerts on your tracked stocks
RQD INSIDER CLUB WAITLIST$49/YR PLANNED
Want Custom AI PineScript / Python Indicators & Priority Rating-Change Alerts?
Join Founding VIP Waitlist (No Card Required) →$100K Arena
EIKN // CANDLESTICK & AUTO-TRENDLINE WORKSTATION6M: -44.69%🛡️ HOLDING TREND SUPPORT
2026-11-03O $5.35H $5.68L $5.31C $5.68VOL 553.1K
RES: $15.32SUP: $4.90SMA50: $8.35SMA200: $10.38
$15.18$12.42$9.67$6.91$4.15RES $15.32SUP $4.90$5.682026-05-042026-06-172026-08-042026-09-182026-11-03
PRIMARY-SOURCE FORENSICS, SECOND-ORDER LINKS & AI ANALYST DESK

EIKN Dilution Monitor, Expectations Hurdle, Butterfly Connections & Policy Exposure

🦋 EIKN Butterfly Map → + Track EIKN →
Share Count & Dilution Monitor

Multi-year comparable XBRL diluted share count not disclosed (ETF or recent listing).

Reverse-DCF Expectations Hurdle
8.0%/yr Implied 5Y Growth

vs. +6.0% actual YoY revenue growth (assuming 9.25% cost of equity & 16.5x terminal multiple).

Ellis Vennor Setup Ledger

No active Ellis Vennor swing setup published on EIKN today. View full Setup Ledger →

🦋 Documented & Second-Order Butterfly Connections Open Graph →

No direct multi-tier Butterfly edges indexed yet for EIKN. Explore sector supply chains on /butterfly.

AI Analyst Theses, Washington Policy & Company Video
🎬 No recent verified company-specific video clip queued for EIKN today (we never pad ticker pages with unrelated generic clips). Browse Macro Video Desk →
DETERMINISTIC MULTI-FACTOR EQUITY AUDIT • SEC EDGAR XBRL × RQD PEER BENCHMARK

📊 Quantitative Sector Peer Comparison, SEC Filing Delta & Investment FAQ (EIKN)

Health Care Rank #410 of 1016 ⚔️ SCTX vs EIKN Full Matrix →

1. Head-to-Head Health Care Peer Comparison (EIKN vs. SCTX, SABS, AGEN, IPSC)

Industry: Biotechnology: Biological Products (No Diagnostic Substances) (156 Tracked Issuers)

Across 1016 tracked Health Care securities in the Roarable RQD universe, Eikon Therapeutics Inc. (EIKN) ranks #410 by composite RQD confidence (43/100, grade D-) and #522 by equity capitalization ($287.6M). Within this direct 5-issuer industry benchmark cohort, SABS leads on earnings valuation at 22.1x trailing P/E, while IPSC leads on capital efficiency and profitability with -14.1% ROIC and — gross margin. EIKN currently leads its immediate peer cohort in composite quantitative strength at 43/100 (D-).

Ticker / Company Roarable Grade RQD Score Trailing P/E Gross Margin ROIC 1D Change Market Cap Head-to-Head
EIKN ACTIVE
Eikon Therapeutics Inc.
D- 43/100 — — — +6.97% $287.6M Benchmark Subject
SCTX
Scribe Therapeutics Inc.
D- 43/100 — — — +0.78% $291.9M /sctx-vs-eikn →
SABS
SAB Biotherapeutics Inc.
D- 38/100 22.1x — -27.4% -1.49% $304.8M /sabs-vs-eikn →
AGEN
Agenus Inc.
E 29/100 — 96.0% -35.0% -4.53% $308.9M /agen-vs-eikn →
IPSC
Century Therapeutics Inc.
E 18/100 — — -14.1% +0.68% $266.2M /ipsc-vs-eikn →

2. Multi-Year SEC XBRL Revenue, Cash Flow & Balance-Sheet Trajectory (FY2025–FY2025)

SEC EDGAR 10-K • FILED 2025-12-31 • CIK 0001861123

In its most recent audited fiscal period (FY2025, filed 2025-12-31), Eikon Therapeutics Inc. (EIKN) reported GAAP revenue of $249.8M , GAAP net income of $0, operating cash flow of $0, and free cash flow of $0 . On the balance sheet, EIKN closed FY2025 with $594.7M in total assets against $0 in total debt (Altman Z-Score: N/A, Piotroski F-Score: N/A).

Fiscal Period Filing Date Revenue Net Income Operating Cash Flow Free Cash Flow Total Assets Total Debt
FY2025 (FY) 2025-12-31 $249.8M $0 — — $594.7M —

3. EIKN Data-Verified Investor FAQ (RQD Rating, Sector Peers, SEC Forensics & Technicals)

✓ SCHEMA.ORG FAQPAGE JSON-LD ENABLED

Is EIKN stock a Buy, Hold, or Sell right now according to Roarable's RQD model?

As of 2026-11-03, Eikon Therapeutics Inc. (NASDAQ: EIKN) is rated D- (Sell / SELL) by Roarable's 5-pillar RQD engine with a composite confidence score of 43/100 at a spot price of $5.68 (+6.97% 1D, market cap $287.6M). Pillar breakdown: Fundamental Cash Engine 10/20, Institutional 13F & Options Flow 3/20, Executive Insider Alignment 13/20, FRED Macro Regime Fit 8/20, and SEC Balance-Sheet Forensics 9/20. Active quantitative signal LIQUIDITY_TAILWIND (BEARISH, conviction undefined/100) notes: undefined.

How does EIKN compare to SCTX and SABS in the Health Care sector?

Within the Health Care sector (Biotechnology: Biological Products (No Diagnostic Substances)), EIKN carries a Roarable D- (43/100 RQD), trailing P/E of N/A, gross margin of —, and ROIC of —. By comparison, SCTX (Scribe Therapeutics Inc.) holds a D- grade (43/100 RQD, P/E N/A, ROIC —, cap $291.9M) and SABS (SAB Biotherapeutics Inc.) posts a D- grade (38/100 RQD, P/E 22.1x, ROIC -27.4%, cap $304.8M). Among the 5-stock peer group, SABS leads on earnings multiple (22.1x) while IPSC leads on capital efficiency (-14.1% ROIC).

What are the biggest fundamental strengths and SEC risk factors for EIKN?

Per EIKN's SEC EDGAR XBRL 10-K filing (FY2025, filed 2025-12-31, CIK 0001861123), Eikon Therapeutics Inc. generated $249.8M in revenue, $0 in net income, and $0 in free cash flow against $594.7M in total assets and $0 in total debt. Key quantitative strengths: Established market leader in Health Care with deep daily trading liquidity.. Primary risk factors monitored: Company executives have done more routine share selling than personal cash buying lately.. Institutional options positioning shows a 50% call / 50% put premium split.

Where is EIKN trading relative to its 50-day, 200-day, and 52-week technical levels?

EIKN last traded at $5.68 (+6.97% on volume of 410,051 shares), positioning the stock -31.98% below its 50-day simple moving average ($8.35) and -45.28% below its 200-day simple moving average ($10.38). Across its 52-week range of $5.01 to $17.40, EIKN sits at the 5.4% percentile with a 14-day RSI of 28.6 (OVERSOLD (<32)) and an implied next-earnings move of ±12.5% ($4.97 to $6.39).

Direct Sub-Reports: EIKN RQD Cockpit EIKN 12M Forecast EIKN Earnings & Move EIKN Dividends & DRIP EIKN Insiders & 13F EIKN Whale Options EIKN Profit Sankey EIKN News & Why
ROARABLE RATING BRIEF • RQD 43/100 (D-) ✓ SEC XBRL & RQD VERIFIED

EIKN — Eikon Therapeutics Inc.: What the Facts Mean to a Prospective Investor

Methodology: RQD v6.2 Deterministic 5-Pillar & SEC XBRL Audit
Updated: 2025-12-31

1. Roarable Rating Brief: What This Means to a Prospective Investor

Eikon Therapeutics Inc. (EIKN) earns a live Roarable RQD composite score of 43/100, corresponding to a D- letter grade (Roarable Sell) at a spot price of $5.68 (+6.97% 1D, market capitalization $287.6M).

  • Fundamental Cash Engine (10/20): Anchored by return on invested capital (ROIC) of —, gross margin of —, operating margin of —, and free cash flow yield of —.
  • Whale 13F & Options Flow (3/20) + Insider Conviction (13/20): Tracks institutional 13F accumulation, CBOE options call/put positioning, and SEC Form 4 / Congressional PTR filings.
  • Macro Regime Fit (8/20) + Forensic Balance Sheet (9/20): Incorporates a 1.00x equity beta, Altman Z-Score of N/A, Piotroski F-Score of N/A, and Debt/Equity of N/A.

2. Business Model, Unit Margins & SEC Financial Trajectory

Eikon Therapeutics Inc. Is listed on NASDAQ and classified under the Health Care sector, within the Biotechnology: Biological Products (No Diagnostic Substances) industry..3B.

In its latest audited SEC EDGAR 10-K filing for FY2025 (filed 2025-12-31), Eikon Therapeutics Inc. (EIKN) reported $249.8M in annual revenue and $0 in GAAP net income. Operating cash flow reached $0 and free cash flow totaled $0, backed by $594.7M in total assets against $0 in total debt.

3. Institutional Bull vs. Bear Thesis & Valuation Tradeoff

  • 🐂 Primary Bull Case (D- • RQD 43/100): Established market leader in Health Care with deep daily trading liquidity. Free cash flow yield of — and institutional whale pillar of 3/20. With Fundamental Cash Engine at 10/20 and Institutional Whale Flow at 3/20, sustained execution supports upside toward the upper end of the $5.01 – $17.40 52-week range.
  • 🐻 Primary Bear Case & Valuation Risk: Company executives have done more routine share selling than personal cash buying lately. Investors must weigh current valuation against — operating margins and a 1.00x macro beta.

4. 2nd-Order Butterfly Ripples & Key Questions to Watch

Upstream and downstream dependencies are therefore — The graph's sector is Health Care and its industry is Biotechnology: Biological Products (No Diagnostic Substances), but no sector-correlation data beyond the liquidity signal is provided. The only second-order channel described in the source is the liquidity linkage: the signal attributes elevated sensitivity to net-liquidity swings, so a tightening or widening move in the cited liquidity measures would be a second-order ripple for this name. Investors should watch the liquidity inputs the signal cites, since the source data identifies them as the primary transmission mechanism.

  • Key Question #1: Can EIKN sustain or expand its — operating margin and — ROIC against Biotechnology: Biological Products (No Diagnostic Substances) peers over the next 4 quarters?
  • Key Question #2: Following FY2025 revenue of $249.8M and free cash flow of $0, how will capital allocation balance growth reinvestment against $0 in total debt?
  • Key Question #3: How sensitive is EIKN's equity valuation to Health Care capital spending cycles and macro interest-rate shifts (Beta 1.00x)?

EIKN Live News Feed, Press Releases & Catalyst Wire

Real-time company headlines, analyst actions, and sector developments for Eikon Therapeutics Inc. (EIKN) • Click "Debate This Headline" to argue it in the Roar Pit below

💬 Jump to EIKN Debate Forum (3) ↓
🔥 THE ROAR PIT • LIVE COMMUNITY DEBATE 3 Active Posts & Replies

EIKN Bull vs. Bear Conversation Board — What's Your Call at $5.68?

🐂 67% BULLISH CONVICTION COMMUNITY TUG-OF-WAR ON EIKN 🐻 33% BEARISH CONVICTION
1. Pick Your Side on EIKN:
💡 Tip: Back up your call with a price target or RQD metric to get upvoted to the top.
DE DeltaGamma_99 RQD DEBATE OPENER • Options Flow Specialist 🐂 BULLISH 🎯 Target: $6.90 (+29.9%)
📌 Pinned Debate

The balance sheet pillar is the rating's strongest input at 13/20, supported by a 2.5 Altman Z-Score and $104.9M in reported cash.

Here is why I am bullish on EIKN here at $5.31: The balance sheet pillar is the rating's strongest input at 13/20, supported by a 2.5 Altman Z-Score and $104.9M in reported cash.. Compare EIKN's 0.0% operating margin and 0.0% ROIC against the rest of Biotechnology: Biological Products (No Diagnostic Substances). As long as cash conversion holds up, dips toward $5.04 are getting bought.

SectorRotator 🐂 BULL

@RiskArb_Desk Fair point on current EV/EBITDA multiples, but you're ignoring the forward operating leverage in Biotechnology: Biological Products (No Diagnostic Substances). If gross margin (0.0%) holds, EPS grows into the multiple faster than bears think.

RI RiskArb_Desk RQD DEBATE OPENER • Hedged Event Driven 🐻 BEARISH 🎯 Target: $4.35 (-18.1%)
Spot @ $5.31

The Butterfly liquidity signal scores a BEARISH 18/100 MACRO TAILWIND with a 4.27x net-liquidity beta, while the company reports $0.0M

The Butterfly liquidity signal scores a BEARISH 18/100 MACRO TAILWIND with a 4.27x net-liquidity beta, while the company reports $0.0M in revenue and 0% ROIC.. Look at the math on EIKN: paying current EV/EBITDA multiples for 0.0% ROIC and 0.0% operating margins leaves zero margin of safety if Biotechnology: Biological Products (No Diagnostic Substances) demand softens. I'd wait for a retest of $4.67 before getting long.

LIVE TAPE SPY $752.10 -1.80% QQQ $681.09 -3.60% DIA $519.34 -1.08% IWM $279.14 -1.68% NVDA $202.06 -1.26% AAPL $338.32 -1.83% MSFT $507.12 -2.83% TSLA $403.82 +1.00% PLTR $178.34 -3.13% SOFI $16.60 -0.95% IBIT $43.35 -5.42% GLD $361.65 -3.59%